• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Trulieve Cannabis (TRLV) Could Be 47% Undervalued Following Its NYSE Debut

    Simply Wall St·08/19/2026 07:32:20
    Listen to the news

    Why Trulieve Cannabis Stock Is Back In Focus After Its NYSE Debut

    Trulieve Cannabis (TRLV) drew fresh attention after ringing the New York Stock Exchange Closing Bell and becoming the first U.S. cannabis company to list on the NYSE. The move signals higher visibility and potentially wider investor access.

    The NYSE listing sits alongside Trulieve Cannabis operations that include 207 medical dispensaries, 5,000 employees, and 3.5 million square feet of cultivation and production capacity across several U.S. states. For investors, this combination of scale and a major exchange listing sets the backdrop for reassessing the stock.

    See our latest analysis for Trulieve Cannabis.

    Trulieve Cannabis has seen momentum build around its NYSE debut, with the share price at $9.69 and a 30-day share price return of 10.24%, while the 1-year total shareholder return of 35.34% contrasts with a 5-year total shareholder return that declined 64.57%.

    If this kind of sector milestone has your attention, it can be a useful moment to broaden your watchlist with other growth stories using the 21 top founder-led companies

    After Trulieve Cannabis stock rallied around its NYSE debut, the key issue now is simple. Has the recent move already reflected most of the good news, or does the current valuation still leave room for further upside potential?

    Most Popular Narrative: 46.7% Undervalued

    With Trulieve Cannabis last closing at $9.69 and the most followed narrative pointing to a fair value of $18.18 using a 7.24% discount rate, the gap between price and narrative value is wide enough to warrant a closer look at what is driving that view.

    A strong cash position of US$353 million against US$290 million in debt and positive free cash flow of US$42 million in the quarter provide room to fund new stores, production upgrades and possible acquisitions, which can influence future revenue and earnings power.

    Read the complete narrative.

    Want to see what sits behind that cash and free cash flow story? The narrative rests on shifting margins, changing revenue expectations and a future earnings multiple that is far from conservative.

    Result: Fair Value of $18.18 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Trulieve Cannabis still faces meaningful uncertainties, including the timing and scope of US federal rescheduling benefits and ongoing pricing pressure that could affect future margins.

    Find out about the key risks to this Trulieve Cannabis narrative.

    Next Steps

    With both clear risks and potential rewards on the table for Trulieve Cannabis, it makes sense to move quickly and test the numbers yourself. To weigh both sides of the story and see how they balance out for your own portfolio, start by reviewing the 3 key rewards and 2 important warning signs

    Looking for more investment ideas beyond Trulieve Cannabis?

    If Trulieve Cannabis has sharpened your focus, do not stop there. Use the Simply Wall Street Screener to spot fresh opportunities that match your investing style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.